

# Kun Cheng

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2176477/publications.pdf>

Version: 2024-02-01

57  
papers

3,305  
citations

147801

31  
h-index

161849

54  
g-index

79  
all docs

79  
docs citations

79  
times ranked

5044  
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of HER2 in cancer therapy and targeted drug delivery. <i>Journal of Controlled Release</i> , 2010, 146, 264-275.	9.9	442
2	Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications. <i>Journal of Controlled Release</i> , 2017, 266, 17-26.	9.9	376
3	Prodrugs for improving tumor targetability and efficiency. <i>Advanced Drug Delivery Reviews</i> , 2011, 63, 659-670.	13.7	283
4	The principles and applications of avidin-based nanoparticles in drug delivery and diagnosis. <i>Journal of Controlled Release</i> , 2017, 245, 27-40.	9.9	193
5	TGF- $\beta$ 1 Gene Silencing for Treating Liver Fibrosis. <i>Molecular Pharmaceutics</i> , 2009, 6, 772-779.	4.6	92
6	Enzyme-responsive polymeric micelles of cabazitaxel for prostate cancer targeted therapy. <i>Acta Biomaterialia</i> , 2020, 113, 501-511.	8.3	88
7	Prostate cancer relevant antigens and enzymes for targeted drug delivery. <i>Journal of Controlled Release</i> , 2014, 187, 118-132.	9.9	86
8	Development of a Peptide-Drug Conjugate for Prostate Cancer Therapy. <i>Molecular Pharmaceutics</i> , 2011, 8, 901-912.	4.6	83
9	The Importance of Apparent pKa in the Development of Nanoparticles Encapsulating siRNA and mRNA. <i>Trends in Pharmacological Sciences</i> , 2021, 42, 448-460.	8.7	76
10	Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy. , 2019, 7, 270.		74
11	Peptides Used in the Delivery of Small Noncoding RNA. <i>Molecular Pharmaceutics</i> , 2014, 11, 3395-3408.	4.6	71
12	siRNA- and miRNA-based therapeutics for liver fibrosis. <i>Translational Research</i> , 2019, 214, 17-29.	5.0	65
13	Comparison of Avidin, Neutravidin, and Streptavidin as Nanocarriers for Efficient siRNA Delivery. <i>Molecular Pharmaceutics</i> , 2017, 14, 1517-1527.	4.6	61
14	Enhanced Hepatic Uptake and Bioactivity of Type $\alpha$ 1(I) Collagen Gene Promoter-Specific Triplex-Forming Oligonucleotides after Conjugation with Cholesterol. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 317, 797-805.	2.5	60
15	The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy. <i>Cancer Letters</i> , 2021, 510, 67-78.	7.2	60
16	Targeted Drug Delivery to Hepatic Stellate Cells for the Treatment of Liver Fibrosis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 370, 695-702.	2.5	58
17	Silencing of the IKK $\mu$ gene by siRNA inhibits invasiveness and growth of breast cancer cells. <i>Breast Cancer Research</i> , 2010, 12, R74.	5.0	55
18	Expression Profile and Functional Activity of Peptide Transporters in Prostate Cancer Cells. <i>Molecular Pharmaceutics</i> , 2013, 10, 477-487.	4.6	53

#	ARTICLE	IF	CITATIONS
19	Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response. , 2020, 8, e001038.		51
20	Intracellular trafficking and exocytosis of a multi-component siRNA nanocomplex. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 1323-1334.	3.3	49
21	Co-delivery of IKBKE siRNA and cabazitaxel by hybrid nanocomplex inhibits invasiveness and growth of triple-negative breast cancer. Science Advances, 2020, 6, eabb0616.	10.3	48
22	Targeted Delivery of a Triplex-Forming Oligonucleotide to Hepatic Stellate Cells. Biochemistry, 2005, 44, 4466-4476.	2.5	45
23	Inhibition of Breast Cancer Cell Growth and Invasiveness by Dual Silencing of HER-2 and VEGF. Molecular Pharmaceutics, 2010, 7, 543-556.	4.6	42
24	Biodistribution and Hepatic Uptake of Triplex-Forming Oligonucleotides against Type I (I) Collagen Gene Promoter in Normal and Fibrotic Rats. Molecular Pharmaceutics, 2005, 2, 206-217.	4.6	41
25	Development of a peptide-modified siRNA nanocomplex for hepatic stellate cells. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 51-61.	3.3	41
26	Gene Modulation for Treating Liver Fibrosis. Critical Reviews in Therapeutic Drug Carrier Systems, 2007, 24, 93-146.	2.2	41
27	Site-Specific Delivery of Oligonucleotides to Hepatocytes after Systemic Administration. Bioconjugate Chemistry, 2008, 19, 290-298.	3.6	39
28	Development of cholesteryl peptide micelles for siRNA delivery. Journal of Controlled Release, 2013, 172, 159-168.	9.9	39
29	Discovery of PSMA-specific peptide ligands for targeted drug delivery. International Journal of Pharmaceutics, 2016, 513, 138-147.	5.2	39
30	Development of a Biocompatible Copolymer Nanocomplex to Deliver VEGF siRNA for Triple Negative Breast Cancer. Theranostics, 2019, 9, 4508-4524.	10.0	37
31	Targeted nanodiamonds as phenotype-specific photoacoustic contrast agents for breast cancer. Nanomedicine, 2015, 10, 573-587.	3.3	34
32	Discovery of Peptide Ligands for Hepatic Stellate Cells Using Phage Display. Molecular Pharmaceutics, 2015, 12, 2180-2188.	4.6	33
33	Chemical Evidence for Potent Xanthine Oxidase Inhibitory Activity of Ethyl Acetate Extract of Citrus aurantium L. Dried Immature Fruits. Molecules, 2016, 21, 302.	3.8	33
34	Development of a Tumor-Responsive Nanopolyplex Targeting Pancreatic Cancer Cells and Stroma. ACS Applied Materials & Interfaces, 2019, 11, 45390-45403.	8.0	33
35	Discovery of Aptamer Ligands for Hepatic Stellate Cells Using SELEX. Theranostics, 2017, 7, 2982-2995.	10.0	32
36	Blocking IKK Expression Inhibits Prostate Cancer Invasiveness. Pharmaceutical Research, 2011, 28, 1357-1369.	3.5	28

#	ARTICLE	IF	CITATIONS
37	An enzyme-responsive conjugate improves the delivery of a PI3K inhibitor to prostate cancer. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 2373-2381.	3.3	25
38	Identification of a LNCaP-Specific Binding Peptide Using Phage Display. <i>Pharmaceutical Research</i> , 2011, 28, 2422-2434.	3.5	24
39	Receptor-Mediated Hepatic Uptake of M6P-BSA-Conjugated Triplex-Forming Oligonucleotides in Rats. <i>Bioconjugate Chemistry</i> , 2006, 17, 823-830.	3.6	23
40	Development of Streptavidin-Based Nanocomplex for siRNA Delivery. <i>Molecular Pharmaceutics</i> , 2013, 10, 4534-4545.	4.6	22
41	A Novel Rapamycin-Polymer Conjugate Based on a New Poly(Ethylene Glycol) Multiblock Copolymer. <i>Pharmaceutical Research</i> , 2014, 31, 706-719.	3.5	22
42	Targeted Delivery of an siRNA/PNA Hybrid Nanocomplex Reverses Carbon Tetrachloride-Induced Liver Fibrosis. <i>Advanced Therapeutics</i> , 2019, 2, 1900046.	3.2	19
43	Studies of Hydroxypropyl Methylcellulose Donut-Shaped Tablets. <i>Drug Development and Industrial Pharmacy</i> , 1999, 25, 1067-1071.	2.0	17
44	Coexpression of Vascular Endothelial Growth Factor and Interleukin-1 Receptor Antagonist for Improved Human Islet Survival and Function. <i>Molecular Pharmaceutics</i> , 2007, 4, 199-207.	4.6	17
45	PCBP2 siRNA Reverses the Alcohol-induced Pro-fibrogenic Effects in Hepatic Stellate Cells. <i>Pharmaceutical Research</i> , 2011, 28, 3058-3068.	3.5	17
46	Silencing PCBP2 normalizes desmoplastic stroma and improves the antitumor activity of chemotherapy in pancreatic cancer. <i>Theranostics</i> , 2021, 11, 2182-2200.	10.0	17
47	Discovery of Small Anti-ACE2 Peptides to Inhibit SARS-CoV-2 Infectivity. <i>Advanced Therapeutics</i> , 2021, 4, 2100087.	3.2	16
48	Cellular protein markers, therapeutics, and drug delivery strategies in the treatment of diabetes-associated liver fibrosis. <i>Advanced Drug Delivery Reviews</i> , 2021, 174, 127-139.	13.7	16
49	Computational Design of Miniproteins as SARS-CoV-2 Therapeutic Inhibitors. <i>International Journal of Molecular Sciences</i> , 2022, 23, 838.	4.1	15
50	Silencing of Î±-complex protein-2 reverses alcohol- and cytokine-induced fibrogenesis in hepatic stellate cells. <i>Liver Research</i> , 2017, 1, 70-79.	1.4	14
51	siRNA Delivery and Targeting. <i>Molecular Pharmaceutics</i> , 2009, 6, 649-650.	4.6	11
52	Evaluation of Extraction and Degradation Methods to Obtain Chickpeasaponin B1 from Chickpea (Cicer) Tj ETQq0 0 0 rgBT /Overlock 10	3.8	11
53	Biological and Therapeutic Applications of Small RNAs. <i>Pharmaceutical Research</i> , 2011, 28, 2961-2965.	3.5	9
54	LMO7 as an Unrecognized Factor Promoting Pancreatic Cancer Progression and Metastasis. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 647387.	3.7	8

#	ARTICLE	IF	CITATIONS
55	Noncovalent Attachment of Chemical Moieties to siRNAs Using Peptide Nucleic Acid as a Complementary Linker. ACS Applied Bio Materials, 2018, 1, 643-651.	4.6	5
56	RNA Interference for Cancer Therapy. , 2009, , 399-440.		4
57	Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy. Frontiers in Immunology, 2022, 13, 838966.	4.8	3